Evidence map›Paper›PMID 35960731›Full record

ArticlePloS one2022

Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort.

Lorena Vigón, Miguel Galán, Montserrat Torres, Antonio J Martín-Galiano, Sara Rodríguez-Mora, Elena Mateos, Magdalena Corona, Rosa Malo, Cristina Navarro, María Aránzazu Murciano-Antón and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Genes · 2024
    Article
  8. Narrative Review Explaining the Role ofInfectious disease reports · 2024
    Review
  9. Article
  10. Review
  11. Tools for Etiologic Diagnosis of Drug-Induced Allergic Conditions.International journal of molecular sciences · 2023
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Lorena VigónImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-6405-4054
Miguel GalánImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-6695-1509
Montserrat TorresImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Antonio J Martín-GalianoIntrahospital Infections Laboratory, National Centre of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Sara Rodríguez-MoraImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Elena MateosImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Magdalena CoronaHematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Rosa MaloNeumology Service, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
Cristina NavarroNeumology Service, Hospital de El Escorial, El Escorial, Spain.
María Aránzazu Murciano-AntónFamily Medicine, Centro de Salud Doctor Pedro Laín Entralgo, Alcorcón, Spain.
Valentín García-GutiérrezHematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Vicente PlanellesDivision of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
Jorge Martínez-LasoImmunogenetic Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
María Rosa López-HuertasImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Mayte CoirasImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-6464-5770
Multidisciplinary Group of Study of COVID-19 (MGS-COVID)
Instituto de Salud Carlos III · ESHospital Universitario Ramón y Cajal · ESCentro de Salud Casa del Barco · ESHospital El Escorial · ESHospital Universitario Puerta de Hierro Majadahonda · ESUniversity of Utah · US

Funding

Tyrosine Kinase inhibition: The New Front in HIV Cure EffortsR01AI143567 · NIAID · UNIVERSITY OF UTAH · PI COIRAS, MAYTE, PLANELLES, VICENTE · 2019 to 2023
$2.3M
NIAID NIH HHS R01 AI143567
6 · The paper itself

Abstract

The clinical presentations of COVID-19 may range from an asymptomatic or mild infection to a critical or fatal disease. Several host factors such as elderly age, male gender, and previous comorbidities seem to be involved in the most severe outcomes, but also an impaired immune response that causes a hyperinflammatory state but is unable to clear the infection. In order to get further understanding about this impaired immune response, we aimed to determine the association of specific HLA alleles with different clinical presentations of COVID-19. Therefore, we analyzed HLA Class I and II, as well as KIR gene sequences, in 72 individuals with Spanish Mediterranean Caucasian ethnicity who presented mild, severe, or critical COVID-19, according to their clinical characteristics and management. This cohort was recruited in Madrid (Spain) during the first and second pandemic waves between April and October 2020. There were no significant differences in HLA-A or HLA-B alleles among groups. However, despite the small sample size, we found that HLA-C alleles from group C1 HLA-C*08:02, -C*12:03, or -C*16:01 were more frequently associated in individuals with mild COVID-19 (43.8%) than in individuals with severe (8.3%; p = 0.0030; pc = 0.033) and critical (16.1%; p = 0.0014; pc = 0.0154) disease. C1 alleles are supposed to be highly efficient to present peptides to T cells, and HLA-C*12:03 may present a high number of verified epitopes from abundant SARS-CoV-2 proteins M, N, and S, thereby being allegedly able to trigger an efficient antiviral response. On the contrary, C2 alleles are usually poorly expressed on the cell surface due to low association with β2-microglobulin (β2M) and peptides, which may impede the adequate formation of stable HLA-C/β2M/peptide heterotrimers. Consequently, this pilot study described significant differences in the presence of specific HLA-C1 alleles in individuals with different clinical presentations of COVID-19, thereby suggesting that HLA haplotyping could be valuable to get further understanding in the underlying mechanisms of the impaired immune response during critical COVID-19.

Indexed as

COVID-19AgedAllelesHLA-C AntigensHumansMalePeptidesPilot ProjectsSARS-CoV-2HLA-C AntigensPeptides

Identifiers

PMID35960731
PMCPMC9374209
OpenAlexW4290851292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.